Safety And Effectiveness Of A New Hydrophobic Bi-Aspheric Iol: Two Years Follow-Up
Published 2023 - 41st Congress of the ESCRS
Reference: PO0265 | Type: Free paper | DOI: 10.82333/wr4t-7598
Authors: Ana Hervás Ontiveros* 1 , Enrique España 2 , Sara Fathi 1 , Rodrigo Butron 1 , Carlos Fresno 3
1Hospital La Fe ,Valencia,Spain, 2Hospital La Fe ,Valencia ,Spain, 3Universidad de Valencia,Valencia,Spain
Purpose
This study assessed safety and effectiveness of a hydrophobic bi-aspheric monofocal intraocular lens (AsqelioTM Monofocal IOL; AST Products, Inc. Massachusetts, U.S.A.).
Setting
La Fé University Hospital, Valencia, Spain
Methods
One hundred and fifty eyes from 75 subjects implanted with the hydrophobic AsqelioTM Monofocal IOL after cataract extraction by phacoemulsification two years prior to enrolment were included. Monocular best corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA) were evaluated. Safety was assessed by monitoring adverse events (AEs). Visual acuity and safety outcomes were compared with historical safety and performance endpoint (SPE) rates.
Results
At 24 months post-implantation, most of the eyes receiving the AsqelioTM IOL achieved monocular UDVA ≤0.1 logMAR; AEs were within SPE limits, as only two cases (1.3%) of posterior capsule opacification were reported. There were no observations of IOL glistening at 24 months.
Conclusions
Results of this study support AsqelioTM Monofocal IOL as effective and safe for implantation after cataract extraction by phacoemulsification.